Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine

Bing Wan; Lu Qin; Weihong Ma; He Wang

doi:10.1186/s13027-022-00417-3

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine

Infect Agent Cancer. 2022 Feb 23;17(1):5. doi: 10.1186/s13027-022-00417-3.

Authors

Bing Wan^#¹, Lu Qin^#¹, Weihong Ma¹, He Wang²

Affiliations

¹ Gynecologist Tumor Department, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Zhong Shan Street, Nanning, 530021, Guangxi Zhuang Autonomous Region, China.
² Gynecologist Tumor Department, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Zhong Shan Street, Nanning, 530021, Guangxi Zhuang Autonomous Region, China. wanghe10430@126.com.

^# Contributed equally.

Abstract

Objective: This study aims to prepare candidate vaccines for cervical cancer immunotherapy by inserting the fused genes of human papillomavirus (HPV)16/18/58 mE6E7 lacking transforming activity into an adenovirus vector and to verify its efficiency in model mice with tumor expressing the associated HPV genes.

Methods: The E6/E7 genes of HPV16/18/58 were point-mutated to abolish their transforming activity, and adenovirus (AD)-HPV16/18/58 mE6E7 adenovirus vaccine was constructed. The immune effect of the adenovirus vaccine against HPV16/18/58-type tumors was analyzed by tumor morphology, enzyme linked immunosorbent assay, enzyme-linked immunospot and specific cytotoxic T lymphocyte (CTL) and T lymphocyte subsets.

Results: The HPV16/18/58 mE6E7 plasmid containing point mutations was verified by quantitative real-time polymerase chain reaction (qRT-PCR), enzyme digestion and electrophoresis, and gene sequencing. qRT-PCR and Western blots verified that AD-HPV16/18/58 mE6E7 could express the HPV16 mE6E7, HPV18 mE6E7 and HPV58 mE6E7 fusion genes and proteins in cells. The results of animal experiments were as follows: In the vaccine group, the tumors formed later, the incubation period was longer, the growth was slower, growth was inhibited, and the survival period was significantly prolonged. The immunological results all showed that the vaccine could induce effective humoral and cellular immunity in mice with three types of tumors, compared with the phosphate buffered saline (PBS) group and the adenovirus-negative control (AD-NC) group, the differences were statistically significant (P < 0.05).

Conclusion: We successfully constructed the HPV16/18/58 trivalent therapeutic adenovirus vaccine AD-HPV16/18/58 mE6E7. The AD-HPV16/18/58 mE6E7 adenovirus vaccine can protect immunized mice to a certain extent from TC-1, U14/LV-HPV18 E6E7 and U14/LV-HPV58 E6E7 cells, which contain HPV16, 18 and 58 E6 and/or E7 genes, respectively.

Keywords: Adenovirus vaccine; E6 and E7 gene; Human papillomavirus type 16/18/58; Immunogenicity; Trivalent therapeutic vaccine.

Abstract

Grants and funding